JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Summary

This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.

Timeline

Start

2023-06-01

Primary completion

2024-12-01

Completion

2025-06-01

Drugs

Indications